Table 4.

Confirmed and new biological activities of azo compounds (40–58) derived from actinomycetes and fungal species

No.	Activity reviewed	Activities confirmed (Pa)	Additional predicted activities (Paa)
40	Not studied	–	Antiinflammatory (0.957) Antineoplastic (0.837) Hemostatic (0.822)
41	Not studied	–	Hemostatic (0.962) Antiinflammatory (0.956) Antineoplastic (0.808)
42	Not studied	–	Antiinflammatory (0.964) Hemostatic (0.952) Antineoplastic (0.833)
43	Not studied	–	Antiinflammatory (0.953) Antineoplastic (0.772) Hemostatic (0.577)
44	Not studied	–	Antiinflammatory (0.961) Antiarthritic (0.849) Antineoplastic (0.781)
45	Insecticide	–	Antieczematic (0.732) Kidney function stimulant (0.701) Preneoplastic conditions (0.677)
46	Insecticide	–	Immunosuppressant (0.647) Antieczematic (0.659) Fibrinolytic (0.606)
47	Not studied	–	Preneoplastic (0.692) Kidney function stimulant (0.631)
48	Not studied	–	Antimutagenic (0.758) Spasmolytic, urinary (0.699) Antineoplastic (0.660)
49	Not studied	–	Antiseborrheic (0.874) Phobic disorders treatment (0.784) Kidney function stimulant (0.752)
50	Not studied	–	Carminative (0.817) Phobic disorders treatment (0.786) Antiseborrheic (0.763)
51	Not studied	–	Antieczematic (0.843) Phobic disorders treatment (0.832) Kidney function stimulant (0.786)
52	Not studied	–	Phobic disorders treatment (0.840) Fibrinolytic (0.720) Preneoplastic conditions (0.703)
53	Not studied	–	Acaricide (0.821) Phobic disorders treatment (0.782) Antiseborrheic (0.773)
54	Not studied	–	Alopecia treatment (0.762) Phobic disorders treatment (0.777) Antiinflammatory, intestinal (0.699)
55	Not studied	–	Phobic disorders treatment (0.916) Antiseborrheic (0.802) Acaricide (0.726)
56	Not studied	–	Phobic disorders treatment (0.700) Preneoplastic conditions treatment (0.606) Immunosuppressant (0.612)
57	Not studied	–	Fibrinolytic (0.640) Acaricide (0.636)
58	Not studied	–	Mucositis treatment (0.831) Immunosuppressant (0.690)

^aOnly activities with Pa > 0.5 are shown